Search Results for "Tingkatan Satu Sejarah Nota"

11:14 EDT 30th October 2014 | BioPortfolio

Matching Channels

None

Matching News

Nota Lepidopterologica goes advanced open access with Pensoft Publishers

(Pensoft Publishers) The Societas Europaea Lepidopterologica has joined forces with Pensoft Publishers to bring the Society's journal Nota Lepidopterologica on the way to open access and innovation. T...

Invoiceware International Selected by Sigma-Aldrich To Simplify Compliance with Brazil's Nota Fiscal E-Invoicing Legislation

ATLANTA, July 1, 2014 /PRNewswire-iReach/ -- Invoiceware International, the largest Latin America Business Network, has been selected by Sigma-Aldrich, a leading Life Science and High Technology compa...

ValiRx CEO on upcoming trial

Dr Satu Vainikka, chief executive of ValiRx (LON:VAL), talks to Proactive Investors about the cancer drug group’s upcoming trial, having just received the go-ahead. The Phase I/II study is for V...

Unusual host preference of a moth species could be useful for biological control

(Pensoft Publishers) A team of Iranian researchers from the Rice Research Institute of Iran have discovered that Gynnodomorpha permixtana, a well-known moth species from Europe and Asia, has changed i...

ValiRx gets MHRA approval for phase I/II cancer trial

ValiRx (LON:VAL) has received the go-ahead from the UK licensing authority (MHRA) for a Phase I/II trial for its lead product in prostate cancer and other advanced solid tumours.  The trial will ...

ValiRx's equity swap agreement with Yorkville comes to an end

ValiRx (LON:VAL) said its equity swap funding arrangement with Yorkville has been terminated early. The arrangement was entered into at the end of 2013 and has been exercised in full by agreement betw...

ValiRx lead treatment moves to human stage cancer trial

ValiRx (LON:VAL) applied to the UK Medicines Agency for permission to carry out a phase I/II trial on VAL201, its lead cancer treatment.   The dose escalation study will assess the safety and tol...

ValiRx to start patient recruitment for lead compound trial

ValiRx (LON:VAL) has received final approval to start its Phase I/II study for its lead compound on advanced prostate and other solid tumour sufferers. Dr Satu Vainikka, chief executive, said it was a...

Matching PubMed Articles

PET imaging of prostate tumors with (18) F-Al-NOTA-MATBBN.

Overexpression of the gastrin-releasing peptide receptor (GRPR) in prostate cancer provides a promising target for detection the disease. MATBBN is a new bombesin analog originating from the GRPR anta...

A 67/68Ga-labeling agent that liberates 67/68Ga-NOTA-methionine by lysosomal proteolysis of parental low molecular weight polypeptides to reduce renal radioactivity levels.

The renal localization of gallium-67 or gallium-68 (67/68Ga)-labeled low molecular weight (LMW) probes such as peptides and antibody fragments constitutes a problem in targeted imaging. Wu et al. prev...

Comparison of 18F-AIF-NOTA-PRGD2 and 18F-FDG Uptake in Lymph Node Metastasis of Differentiated Thyroid Cancer.

A widespread application of integrin αvβ3 imaging has been emerging in both pre-clinical and clinical studies. But few studies reported its value as compared with 18F-FDG PET, especially for differe...

The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a 68Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin.

The overexpression of gastrin-releasing peptide receptor (GRPR) in cancer can be used for peptide-receptor mediated radionuclide imaging and therapy. We have previously shown that an antagonist analog...

(68)Ga-NOTA-CHSg and (99m)Tc-CHSg Labeled Microspheres for Lung Perfusion and Liver Radiomicrospheres Therapy Planning.

Fast biodegradable (12 h < half-life < 48 h) radioactive labeled microspheres are needed for PET and SPECT lung perfusion and radiomicrosphere therapy planning. An emulsion method was used to crea...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement